Embodiments of the invention describe to methods of diagnosing, classifying, and/or identifying a patient's risk of developing graft versus host disease, including severe or lethal graft versus host disease, after receiving hematopoietic cellular transplantation, a transfusion or a transplantation, but before the onset of clinical symptoms.

New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.

The present disclosure generally relates to methods for diagnosing, predicting and treating graft-vs-host disease and/or relapse of a hematologic malignancy following hematopoietic stem cell transplantation based on T-cell specific biomarkers.

The present invention relates to the field of organ transplant and the issues associated with transplant rejection. Anti-body-mediated rejection (AMR) is associated with a poor transplant outcome. Pathogenic alloantibodies are usually directed against human leucocyte antigens (HLAs). However, evidence of AMR in the absence of anti-HLA antibodies suggests the presence of non-anti-HLA antibodies, identified as anti-endothelial cell antibodies (AECAs). The inventors have demonstrated that kidney recipients who experienced acute rejection with microvascular inflammation within the first 3 months after transplantation in the absence of anti-HLA donor-specific antibodies, carried, before transplantation, unknown AECAs in their sera that specifically targeted the glomerular microvascular endothelium. Thus, the present invention relates to in vitro methods and kits for determining the likelihood of occurrence of an acute microvascular rejection (AMVR) against a renal allograft in an individual.

The present invention provides a method for assessing the possibility of onset or progression of chronic kidney allograft rejection or chronic kidney disease in a test subject, by using, as an indicator, the level of SYT17 protein in a urine-derived specimen collected from the test subject. The present invention also provides: a pharmaceutical composition for preventing and/or treating chronic kidney allograft rejection or chronic kidney disease, the pharmaceutical composition including at least one substance selected from the group consisting of a specific antibody to SYT17, a derivative of the specific antibody, and an inhibitory nucleic acid against SYT17; and a test kit for use in assessing the possibility of onset or progression of chronic kidney allograft rejection or chronic kidney disease, the test kit including a specific antibody to SYT17 or a derivative of the specific antibody.

A method to determine the severity of a disease of chronic inflammation in a patient, comprising the steps of (1) collection or preparation of a bodily fluid, tissue or lavage and (2) measurement of ALX receptor ligands or ALX receptor expression in the fluid, tissue, or lavage, wherein the level of ALX receptor ligands predicts a clinical outcome or choice of treatment modality, is disclosed.

The present invention relates to urine protein markers of renal damage or pathological phenotype and methods using thereof. It further relates to urine protein markers for determining the degree of fibrosis in a kidney and methods using thereof. In particular, it relates to methods using said biomarkers in monitoring patient's suffering from chronic kidney disease or further to renal transplantation. It further pertains to associated second medical uses, methods of treatment, kits and use thereof in the methods of the invention.

Aspects of the present invention relate to the assessment of explant organ viability prior to transplantation. Particularly, although not exclusively, aspects of the present invention relate to biomarkers which can be used to inform a decision as to whether an organ is suitable for transplantation into a recipient. In certain embodiments, the organ is undergoing hypothermic perfusion following retrieval from a donor.

Methods and kits for screening, diagnosing, detecting or predicting a patient outcome/risk variable for a lung transplant recipient after transplant or an EVLP outcome by measuring biomarker levels of at least three biomarkers selected from IL-6, IL-8, IL-10 and IL-1β optionally in combination with one or both of sTNFR1 and sTREM1 in EVLP perfusate are described. The methods involve for example, i. obtaining one or more test EVLP perfusate samples of a donor lung; ii. determining in one or more test EVLP perfusate sample of a donor lung, a polypeptide level of the at least three biomarkers selected from IL-8, IL-6, IL-10 and IL-1β and optionally one or both of sTNFR1 and sTREM1 i; and iii. a) comparing the one or more parameter values related to a level of the at least three biomarkers in the perfusate sample with control EVLP data or a cut-off level, wherein the differential level is indicative of outcome/risk of after transplant or of an EVLP outcome; or b) using the one or more parameter values related to a level of the at least three biomarkers in combination, as part of an algebraic calculation or model of outcome/risk.

Methods for monitoring the viability of a donor organ before and after transplant based on detection and analysis of whole cells released from the organs.